Appropriate use of low-dose aspirin for primary and secondary
cardiovascular event prevention could improve patient outcomes with significant
cost savings to payers, according to a recent study published in the Journal of
Managed Care & Specialty Pharmacy.
The study compared current rates of aspirin use to appropriate
guideline-recommended aspirin use and found that aspirin is underused in the
U.S. It suggests that clinical evidence-based, guideline-compliant use of
aspirin for primary and secondary cardiovascular event prevention would result
in $4.2 million and $11 million, respectively, in cost savings for a
hypothetical 1-million-member plan over a five-year period. The charts below
detail estimated savings and medical events for the hypothetical population.
SOURCE: Journal
of Managed Care & Specialty Pharmacy. 2018;24(11):1102-11.
Visit https://www.jmcp.org/doi/full/10.18553/jmcp.2018.24.11.1102.
No comments:
Post a Comment